This study aims to evaluate a new PET tracer targeting FAP for better imaging of tumors.
Pilot clinical study conducted to test the novel tracer F]AlF-AA-FAPT.
Comparison made with current FAPI tracers to assess improvements in imaging properties.
F]AlF-AA-FAPT shows an excellent target-to-background ratio compared to existing tracers.
Demonstrates improved pharmacokinetic properties over current FAPI options.
Abstract
F]AlF-AA-FAPT demonstrates excellent target-to-background ratio and improves pharmacokinetic properties, making it an effective alternative to current FAPI tracers.